CTSA Program Posters

The Irving Institute for Clinical and Translational Research, home to Columbia University’s CTSA Program Hub, provides resources to investigators in the areas of precision medicine and translational research through two unique resources focused on providing funding, education, research services, and mentorship programs to support advancement of projects. The Translational Therapeutics (TRx)

A Blue Ribbon taskforce convened in 2005 concluded that in order to effectively advance medical care in a region, “a strong translational research enterprise needed to be developed which could take basic discoveries from the laboratories, translate them into drugs and therapeutic devices, manage animal testing and clinical trials, and get them in the hands of groups that can advance them to market

The University of Florida and Florida State University Clinical and Translational Science Institute Hub (UF & FSU-CTSI Hub) through its partnership immediately launched a COVID-19 Taskforce, spanning both institutions. Taskforce working groups began addressing both local and hub issues covering: Laboratory Research; Clinical Research; Outcomes Research; Education & Workforce Development Solutions

The Mayo Clinic COVID-19 Task Force was established to enable, coordinate, and catalog research studies and practice demands of COVID-19. The task force manages research across the whole translational spectrum, aligning competing and duplicative studies to steward research resources and coordinates Institutional Review Board, Center for Clinical and Translational Science (CCaTS) Office of Clinical

Optional functions at the Scripps Hub include drug repurposing (Calibr, a Division of Scripps Research) and genomics (Rady Children’s Institute for Genomic Medicine; RCIGM). Calibr’s drug repurposing library ReFRAME (Repurposing, Focused Rescue, and Accelerated Medchem) contains nearly all small molecules in any phase of clinical development (~12,000). RCIGM streamlines genomic sequencing for

The Institute for Translational Medicine (ITM) aims to make research breakthroughs happen and to put those discoveries into the real world to improve health. The ITM is a partnership between the University of Chicago and Rush in collaboration with Advocate Health Care, the Illinois Institute of Technology, Loyola University Chicago, and NorthShore University HealthSystem. The goal of the ITM

Columbia University CTSA Program Hub Innovations:​ Operating a Clinical Research Unit in the COVID-19 Era and Building a COVID-19 Biobank​ Heather Seid, MS, RDN (1); Sheila O’Byrne, PhD (2); Elisabeth DiMaria, MHA (1); Ismael Castaneda, MS, BSN (1); Dianne Frederick (1); Janelle Nunez (1); Ariella Kelin, MSRN (3); Josh Wansley, MSRN (3); Danielle Pendrick, DrPH (4); Jennifer Williamson, MS, MPH (5

AZD1222 is being developed for the prevention of COVID-19. AZD1222 is a recombinant replication-defective chimpanzee adenovirus expressing the SARS-CoV-2 S surface glycoprotein, commonly known as the “Oxford vaccine” or as “ChAdOx.” We describe a “scale up” approach utilizing CTSA resources to conduct a multisite clinical trial testing a COVID vaccine in the midst of a pandemic incorporating at

A core aspiration of the CTSA program is to enable all Hubs to operate as a synergistic network, pooling data and knowledge, expanding the scope of observational and interventional trials, and dramatically reducing the time and cost for biomedical discovery and evaluation. The CD2H cores are building the informatics prerequisites necessary to realize this vision.

While there is universal recognition of the importance of team science and team leadership in clinical and translational science, there is a remarkable dearth of valid and reliable outcome measures on team science leadership. As a result, we developed a semi-quantitative translational science-specific team leadership competency assessment tool and have begun pilot studies to validate it and use it